Cargando…

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Bortezomib is a highly selective, reversible inhibitor of the 26S proteasome that is indicated for single-agent use in the treatment of patients with multiple myeloma who have received at least 2 prior therapies and are progressing on their most recent therapy. Clinical investigations have been comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccadoro, Mario, Morgan, Gareth, Cavenagh, Jamie
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1164423/
https://www.ncbi.nlm.nih.gov/pubmed/15929791
http://dx.doi.org/10.1186/1475-2867-5-18

Ejemplares similares